Overview

* Xencor ( XNCR ) Q3 revenue of $21 mln missed analyst expectations

* Net loss for Q3 reduced to $6 mln from $46.3 mln last year

* Company advances clinical programs in oncology and autoimmune diseases

Outlook

* Xencor ( XNCR ) expects to end 2025 with $570 mln to $590 mln in cash

* Company plans pivotal studies for XmAb819 and XmAb541 in 2027

* Xencor ( XNCR ) to start XmAb657 clinical studies by end of 2025

Result Drivers

* REVENUE MISS - Q3 revenue rose to $21 mln primarily due to non-cash royalty revenue from Alexion and Incyte

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $21 mln $27.15

Revenue mln (12

Analysts

)

Q3 EPS -$0.08

Q3 Net -$6.03

Income mln

Q3 $68.52

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Xencor Inc ( XNCR ) is $27.00, about 49.3% above its November 4 closing price of $13.70

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)